Authorized purpose: Concurrent-read CADe to aid physicians in detecting and localizing chest-radiograph ROIs labeled aortic calcification or dilated aorta, suggestive of aortic atherosclerosis or aortic ectasia; it does not replace the physician or other standard-of-care testing.
Clinical role
Concurrent-reading physician aid that generates a DICOM overlay which can be toggled in a PACS viewer while the physician interprets the chest-radiograph study.
Images and patients
X-ray/Radiography · Aorta and thoracic aortic findings on chest radiographs
Key limitation
Keep in mind: Adult use only. Aorta-CAD is a concurrent-reading aid and does not replace the physician or other diagnostic testing in the standard of care. The ROI labels are findings suggestive of chronic aortic conditions, not a standalone diagnosis; the packet does not establish use outside adult chest radiographs or the described PACS review workflow.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Concurrent-read CADe to aid physicians in detecting and localizing chest-radiograph ROIs labeled aortic calcification or dilated aorta, suggestive of aortic atherosclerosis or aortic ectasia; it does not replace the physician or other standard-of-care testing.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Aorta and thoracic aortic findings on chest radiographs Input: Digital chest radiograph studies from adult patients; the FDA comparison identifies digital X-ray input and secure cloud-based processing and delivery, with the output viewed on a PACS system.
Who uses it?Intended users: Physicians
What does the software produce?Output: A DICOM Presentation State file for each image in the study. When an ROI is detected, the overlay contains bounding boxes labeled Aortic calcification or Dilated aorta and text suggesting Aortic Atherosclerosis or Aortic Ectasia; when none is detected, the overlay states No Aorta-CAD ROI(s) and contains no bounding boxes.
What is its most important limitation?Key limitation: Adult use only. Aorta-CAD is a concurrent-reading aid and does not replace the physician or other diagnostic testing in the standard of care. The ROI labels are findings suggestive of chronic aortic conditions, not a standalone diagnosis; the packet does not establish use outside adult chest radiographs or the described PACS review workflow.
Clinical takeaway. Clinical role: Concurrent-read CADe to aid physicians in detecting and localizing chest-radiograph ROIs labeled aortic calcification or dilated aorta, suggestive of aortic atherosclerosis or aortic ectasia; it does not replace the physician or other standard-of-care testing.
Evidence takeaway. Evidence from the reviewed source record: FDA standalone testing assessed 5,000 chest radiograph cases representative of the intended population. Overall sensitivity was 0.910 (95% Wilson CI 0.896-0.922), specificity was 0.896 (0.889-0.902), and ROC AUC was 0.974 (95% bootstrap CI 0.971-0.977). Category results were separate: aortic-calcification sensitivity/specificity 0.922/0.894 and dilated-aorta sensitivity/specificity 0.830/0.897. A fully crossed MRMC reader study used 244 cases and found aided-versus-unaided reader AUC improvements of 0.0984 for aortic calcification and 0.0885 for dilated aorta, both with p-values below 0.001.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Concurrent-read CADe to aid physicians in detecting and localizing chest-radiograph ROIs labeled aortic calcification or dilated aorta, suggestive of aortic atherosclerosis or aortic ectasia; it does not replace the physician or other standard-of-care testing.
Concurrent-reading physician aid that generates a DICOM overlay which can be toggled in a PACS viewer while the physician interprets the chest-radiograph study.
Digital chest radiograph studies from adult patients; the FDA comparison identifies digital X-ray input and secure cloud-based processing and delivery, with the output viewed on a PACS system.
A DICOM Presentation State file for each image in the study. When an ROI is detected, the overlay contains bounding boxes labeled Aortic calcification or Dilated aorta and text suggesting Aortic Atherosclerosis or Aortic Ectasia; when none is detected, the overlay states No Aorta-CAD ROI(s) and contains no bounding boxes.
Adult use only. Aorta-CAD is a concurrent-reading aid and does not replace the physician or other diagnostic testing in the standard of care. The ROI labels are findings suggestive of chronic aortic conditions, not a standalone diagnosis; the packet does not establish use outside adult chest radiographs or the described PACS review workflow.
FDA standalone testing assessed 5,000 chest radiograph cases representative of the intended population. Overall sensitivity was 0.910 (95% Wilson CI 0.896-0.922), specificity was 0.896 (0.889-0.902), and ROC AUC was 0.974 (95% bootstrap CI 0.971-0.977). Category results were separate: aortic-calcification sensitivity/specificity 0.922/0.894 and dilated-aorta sensitivity/specificity 0.830/0.897. A fully crossed MRMC reader study used 244 cases and found aided-versus-unaided reader AUC improvements of 0.0984 for aortic calcification and 0.0885 for dilated aorta, both with p-values below 0.001.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA standalone testing assessed 5,000 chest radiograph cases representative of the intended population. Overall sensitivity was 0.910 (95% Wilson CI 0.896-0.922), specificity was 0.896 (0.889-0.902), and ROC AUC was 0.974 (95% bootstrap CI 0.971-0.977). Category results were separate: aortic-calcification sensitivity/specificity 0.922/0.894 and dilated-aorta sensitivity/specificity 0.830/0.897. A fully crossed MRMC reader study used 244 cases and found aided-versus-unaided reader AUC improvements of 0.0984 for aortic calcification and 0.0885 for dilated aorta, both with p-values below 0.001.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Aorta-CAD regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K213353
Samplen=5000
IndependenceIndependence not established
K213353
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K213353. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Digital chest radiograph studies from adult patients; the FDA comparison identifies digital X-ray input and secure cloud-based processing and delivery, with the output viewed on a PACS system.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA comparison describes secure cloud-based processing and delivery of digital chest radiographs to a PACS, and the device returns a DICOM Presentation State overlay that the physician can toggle in the PACS viewer. Specific interface versions, local compatibility, and current commercial data-flow or hosting details are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the Aorta-CAD platform as secure cloud-based processing and delivery of chest radiographs. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Platform Secure cloud-based processing Secure cloud-based processing and delivery of chest radiographs". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: A DICOM Presentation State file for each image in the study. When an ROI is detected, the overlay contains bounding boxes labeled Aortic calcification or Dilated aorta and text suggesting Aortic Atherosclerosis or Aortic Ectasia; when none is detected, the overlay states No Aorta-CAD ROI(s) and contains no bounding boxes.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A DICOM Presentation State file for each image in the study. When an ROI is detected, the overlay contains bounding boxes labeled Aortic calcification or Dilated aorta and text suggesting Aortic Atherosclerosis or Aortic Ectasia; when none is detected, the overlay states No Aorta-CAD ROI(s) and contains no bounding boxes.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the Aorta-CAD platform as secure cloud-based processing and delivery of chest radiographs. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Platform Secure cloud-based processing Secure cloud-based processing and delivery of chest radiographs". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA comparison describes secure cloud-based processing and delivery of digital chest radiographs to a PACS, and the device returns a DICOM Presentation State overlay that the physician can toggle in the PACS viewer. Specific interface versions, local compatibility, and current commercial data-flow or hosting details are not established.
Imagen's security policy (effective 2024-04-02) states HIPAA, HITRUST CSF and SOC 2 Type II compliance, encryption in transit and at rest, least-privilege access, multi-factor authentication, audit trails and incident response. Vendor statement; no report or certificate was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the policy is on imagen.ai, whose AI software page lists this product by name, and the FDA letter for this entry names Imagen Technologies, Inc. (New York). The policy is company-wide; exact-release scope is not established. A 2023 HITRUST release names the Care Delivery Services platform, not the devices, and is not applied.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K213353 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.
Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Authorized purpose: Analyze frontal chest and abdominal X-ray images to detect and localize a nasally or orally inserted enteric tube, its tip and side port if present, and the diaphragm and airways for radiologist review.
Modality
X-ray/Radiography
Anatomy
Chest/lung and abdomen/stomach; enteric tube, tube tip and side port, diaphragm, and airways including carina and left/right bronchi
Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.
Modality
X-ray/Radiography
Anatomy
Chest/Lung; pleura, mediastinum/hila/heart, bone, hardware and other chest-radiograph regions
Authorized purpose: Provides automated concurrent-read detection and segmentation of caries on bitewing radiographs in patients 18 and older, adding information for the dentist while requiring complete dentist review and judgment.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.